Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.37 |
| ▸ | S1PR4 | O95977 | 4/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 3/20 | 0.35 |
| ▸ | PPARA | Q07869 | 3/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | FABP4 | P15090 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7521983 | 0.97 | PPARD (0.38) | PPARDMEN1KMT2AUSP2PKM | |
| SCHEMBL7527059 | 0.89 | PPARD (0.39) | PPARDMEN1KMT2AUSP2PKM | |
| SCHEMBL7523867 | 0.89 | PPARD (0.40) | PPARDMEN1KMT2AUSP2PKM | |
| SCHEMBL7527935 | 0.86 | PPARD (0.41) | PPARDMEN1KMT2AUSP2PKM | |
| SCHEMBL7974188 | 0.83 | PPARG (0.37) | MEN1KMT2AS1PR5S1PR4PPARG | |
| SCHEMBL7530733 | 0.80 | PTGIR (0.39) | MEN1KMT2APTGDR2POLB | |
| SCHEMBL7521238 | 0.79 | PTGIR (0.42) | MEN1KMT2APPARGPPARAPOLB | |
| SCHEMBL7532260 | 0.77 | PTGIR (0.39) | MEN1KMT2AUSP2PTGDR2POLB | |
| SCHEMBL7523175 | 0.76 | PTGIR (0.41) | PPARDMEN1KMT2AUSP2PKM | |
| SCHEMBL7520987 | 0.75 | PPARD (0.49) | PPARDPTGDR2PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6417213-B2 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-09 | — | — | US | disclosed |
| US-20020006944-A1 | Tricyclic compounds, their production and use | OHKAWA SHIGENORI (JP) | 2002-01-17 | — | — | US | disclosed |
| US-6248766-B1 | CARDIOVASCULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020006944-A1 | Tricyclic compounds, their production and use | CNR1, PTGER1, PTGDR | PPARD 942/4885MEN1 2854/4885KMT2A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.